Vigil Neuroscience (VIGL) Stock Price, News & Analysis

Company Overview

Vigil Neuroscience is a clinical-stage biotechnology company dedicated to developing immune-based therapeutics for neurodegenerative disorders. Headquartered in South San Francisco, the company leverages a proprietary platform that integrates immunosequencing and cellular profiling to uncover the immune drivers of diseases affecting the central nervous system. Vigil’s research focuses on translating insights into novel therapeutic candidates designed to modulate pathogenic immune responses in the brain and spinal cord.

At the core of Vigil’s approach is its ImmunoSignature™ discovery platform, which enables high-resolution analysis of cerebrospinal fluid and peripheral blood cells from patients with conditions such as multiple sclerosis, Alzheimer’s disease and other neurodegenerative syndromes. By identifying disease‐associated immune cells and pathways, the company prioritizes targets that are most likely to deliver meaningful clinical benefit with an improved safety profile compared to broadly immunosuppressive treatments.

Vigil’s pipeline features VGL101, an antibody‐drug conjugate currently in early clinical evaluation for progressive multiple sclerosis, as well as preclinical programs aimed at addressing Alzheimer’s disease and amyotrophic lateral sclerosis. The company collaborates with academic institutions and industry partners to advance its candidates through IND-enabling studies and human trials, with a goal of bringing first-in-class therapies to patients in need.

Founded in 2019, Vigil Neuroscience is led by CEO Gustavo Suter de Py and a management team with extensive experience in neurology, immunology and drug development. With operations spanning North America and Europe, Vigil is positioned to expand its global reach through strategic alliances and ongoing clinical research initiatives.

Key Stats

• Today's Range: $8.07 to $8.09
• 50-Day Range: $2.31 to $8.08
• 52-Week Range: $1.31 to $8.10
• Volume: 3.94 million shs
• Average Volume: 706,739 shs
• Market Capitalization: $384.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.80
• Consensus Rating: Hold

Vigil Neuroscience Stock Analysis - MarketRank™

Vigil Neuroscience scored higher than 74% of companies evaluated by MarketBeat, and ranked 280th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Vigil Neuroscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 10 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Vigil Neuroscience has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vigil Neuroscience are expected to grow in the coming year, from ($2.07) to ($2.03) per share.

Price to Book Value per Share Ratio

Vigil Neuroscience has a P/B Ratio of 4.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.28% of the float of Vigil Neuroscience has been sold short.

Short Interest Ratio / Days to Cover

Vigil Neuroscience has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vigil Neuroscience has recently decreased by 65.75%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vigil Neuroscience does not currently pay a dividend.

Dividend Growth

Vigil Neuroscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.28% of the float of Vigil Neuroscience has been sold short.

Short Interest Ratio / Days to Cover

Vigil Neuroscience has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vigil Neuroscience has recently decreased by 65.75%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.72

News Sentiment

Vigil Neuroscience has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Vigil Neuroscience this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for VIGL on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vigil Neuroscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.01% of the stock of Vigil Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

83.64% of the stock of Vigil Neuroscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VIGL Stock Analysis - Frequently Asked Questions

How have VIGL shares performed this year?

Vigil Neuroscience's stock was trading at $1.70 on January 1st, 2025. Since then, VIGL shares have increased by 374.7% and is now trading at $8.07.

How were Vigil Neuroscience's earnings last quarter?

Vigil Neuroscience, Inc. (NASDAQ:VIGL) announced its earnings results on Wednesday, May, 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04.

When did Vigil Neuroscience IPO?

Vigil Neuroscience (VIGL) raised $112 million in an initial public offering on Friday, January 7th 2022. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share.

Who are Vigil Neuroscience's major shareholders?

Vigil Neuroscience's top institutional investors include Deltec Asset Management LLC (0.06%). Insiders that own company stock include Ivana Magovcevic-Liebisch, Haeberlein Samantha L Budd and Spyros Papapetropoulos.
View institutional ownership trends.

How do I buy shares of Vigil Neuroscience?

Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vigil Neuroscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vigil Neuroscience investors own include NVIDIA (NVDA), Meta Platforms (META), Exxon Mobil (XOM), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Home Depot (HD).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VIGL
• CIK: 1827087
• Web: vigilneuro.com
• Phone: 857-254-4445
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Vigil Neuroscience: $10.80
• High Price Target: $22.00
• Low Price Target: $8.00
• Potential Upside/Downside: +33.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$84.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -111.70%
• Return on Assets: -74.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.97
• Quick Ratio: 2.97

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.75 per share
• Price / Book: 4.61

Miscellaneous

• Outstanding Shares: 47,690,000
• Free Float: 39,099,000
• Market Cap: $385.10 million
• Optionable: Not Optionable
• Beta: 3.34